Back

Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes

26 August 2017 (12:35 - 13:25)
Organised by:
Congress Presentation Part of: Lipid-lowering therapy: old faces and new issues Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Konstantinos Koskinas

Bern University Hospital, Inselspital, Bern (Switzerland)

6 More presentations in this session

Presentation thumbnail
Statin use among HIV-infected adults by cardiovascular disease risk status
Doctor R. Rosenson (New York City, US)
Abstract Slides
Presentation thumbnail
Adipose tissue content of alpha-linolenic acid and the risk of ischemic stroke - A danish case-cohort study
Mr C. Bork (Aalborg, DK)
Abstract Slides
Presentation thumbnail
Low density lipoprotein cholesterol levels at first follow-up after acute myocardial infarction predicts recurrent atherosclerotic cardiovascular disease events poorly.
Doctor J. Ohm (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Significant correlation of vascular and haematopoietic tissue FDG uptake in genetic dyslipidaemia sub-types
Doctor G. Benetos (Athens, GR)
Abstract Slides
Presentation thumbnail
Low LDL-cholesterol goal attainment 4 months after ACS due to lack of adjustment in lipid lowering treatment: Results from DYSIS II
Doctor A. Gitt (Ludwigshafen, DE)
Abstract Slides

Access the full session

Session thumbnail
Lipid-lowering therapy: old faces and new issues

The Event

Event poster

ESC Congress 2017

26 August 2017 12:35 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources